Hubbry Logo
Open search
logo
Open search
Route of administration
Community hub

Route of administration

logo
0 subscribers

Wikipedia

from Wikipedia
Oral administration of a liquid.

In pharmacology and toxicology, a route of administration is the way by which a drug, fluid, poison, or other substance is taken into the body.[1]

Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration. Routes can also be classified based on where the target of action is. Action may be topical (local), enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but is delivered by routes other than the GI tract). Route of administration and dosage form are aspects of drug delivery.

Classification

[edit]

Routes of administration are usually classified by application location (or exposition).

The route or course the active substance takes from application location to the location where it has its target effect is usually rather a matter of pharmacokinetics (concerning the processes of uptake, distribution, and elimination of drugs). Exceptions include the transdermal or transmucosal routes, which are still commonly referred to as routes of administration.

The location of the target effect of active substances is usually rather a matter of pharmacodynamics (concerning, for example, the physiological effects of drugs[2]). An exception is topical administration, which generally means that both the application location and the effect thereof is local.[3]

Topical administration is sometimes defined as both a local application location and local pharmacodynamic effect,[3] and sometimes merely as a local application location regardless of location of the effects.[4][5]

By application location

[edit]

Enteral/gastrointestinal route

[edit]

Through the gastrointestinal tract is sometimes termed enteral or enteric administration (literally meaning 'through the intestines'). Enteral/enteric administration usually includes oral[6] (through the mouth) and rectal (into the rectum)[6] administration, in the sense that these are taken up by the intestines. However, uptake of drugs administered orally may also occur already in the stomach, and as such gastrointestinal (along the gastrointestinal tract) may be a more fitting term for this route of administration. Furthermore, some application locations often classified as enteral, such as sublingual[6] (under the tongue) and sublabial or buccal (between the cheek and gums/gingiva), are taken up in the proximal part of the gastrointestinal tract without reaching the intestines. Strictly enteral administration (directly into the intestines) can be used for systemic administration, as well as local (sometimes termed topical), such as in a contrast enema, whereby contrast media are infused into the intestines for imaging. However, for the purposes of classification based on location of effects, the term enteral is reserved for substances with systemic effects.

A medical professional injects medication into a gastric tube.

Many drugs as tablets, capsules, or drops are taken orally. Administration methods directly into the stomach include those by gastric feeding tube or gastrostomy. Substances may also be placed into the small intestines, as with a duodenal feeding tube and enteral nutrition. Enteric coated tablets are designed to dissolve in the intestine, not the stomach, because the drug present in the tablet causes irritation in the stomach.

Administering medication rectally

The rectal route is an effective route of administration for many medications, especially those used at the end of life.[7][8][9][10][11][12][13] The walls of the rectum absorb many medications quickly and effectively.[14] Medications delivered to the distal one-third of the rectum at least partially avoid the "first pass effect" through the liver, which allows for greater bio-availability of many medications than that of the oral route. Rectal mucosa is highly vascularized tissue that allows for rapid and effective absorption of medications.[15] A suppository is a solid dosage form that fits for rectal administration. In hospice care, a specialized rectal catheter, designed to provide comfortable and discreet administration of ongoing medications provides a practical way to deliver and retain liquid formulations in the distal rectum, giving health practitioners a way to leverage the established benefits of rectal administration. The Murphy drip is an example of rectal infusion.

Parenteral route

[edit]
Needle insertion angles for 4 types of parenteral administration of medication: intramuscular, subcutaneous, intravenous, and intradermal injection.

The parenteral route is any route that is not enteral (par- + enteral).

Parenteral administration can be performed by injection, that is, using a needle (usually a hypodermic needle) and a syringe,[16] or by the insertion of an indwelling catheter.

Locations of application of parenteral administration include:

  • Central nervous system:
  • Epidural (synonym: peridural) (injection or infusion into the epidural space), e.g. epidural anesthesia.
  • Intracerebral (into the cerebrum) administration by direct injection into the brain. Used in experimental research of chemicals[17] and as a treatment for malignancies of the brain.[18] The intracerebral route can also interrupt the blood brain barrier from holding up against subsequent routes.[19]
  • Intracerebroventricular (into the cerebral ventricles) administration into the ventricular system of the brain. One use is as a last line of opioid treatment for terminal cancer patients with intractable cancer pain.[20]
A transdermal patch which delivers medication is applied to the skin. The patch is labelled with the time and date of administration as well as the administrator's initials.
A medical professional applies nose drops.
Topical ocular administration

Topical route

[edit]

The definition of the topical route of administration sometimes states that both the application location and the pharmacodynamic effect thereof is local.[3]

In other cases, topical is defined as applied to a localized area of the body or to the surface of a body part regardless of the location of the effect.[4][5] By this definition, topical administration also includes transdermal application, where the substance is administered onto the skin but is absorbed into the body to attain systemic distribution.

If defined strictly as having local effect, the topical route of administration can also include enteral administration of medications that are poorly absorbable by the gastrointestinal tract. One such medication is the antibiotic vancomycin, which cannot be absorbed in the gastrointestinal tract and is used orally only as a treatment for Clostridioides difficile colitis.[24]

Choice of routes

[edit]

The choice of routes of drug administration is governed by various factors:

  • Physical and chemical properties of the drug. The physical properties are solid, liquid and gas. The chemical properties are solubility, stability, pH, irritancy etc.
  • Site of desired action: the action may be localised and approachable or generalised and not approachable.
  • Rate of extent of absorption of the drug from different routes.
  • Effect of digestive juices and the first pass metabolism of drugs.
  • Condition of the patient.

In acute situations, in emergency medicine and intensive care medicine, drugs are most often given intravenously. This is the most reliable route, as in acutely ill patients the absorption of substances from the tissues and from the digestive tract can often be unpredictable due to altered blood flow or bowel motility.

Convenience

[edit]

Enteral routes are generally the most convenient for the patient, as no punctures or sterile procedures are necessary. Enteral medications are therefore often preferred in the treatment of chronic disease. However, some drugs can not be used enterally because their absorption in the digestive tract is low or unpredictable. Transdermal administration is a comfortable alternative; there are, however, only a few drug preparations that are suitable for transdermal administration.

Desired target effect

[edit]

Identical drugs can produce different results depending on the route of administration. For example, some drugs are not significantly absorbed into the bloodstream from the gastrointestinal tract and their action after enteral administration is therefore different from that after parenteral administration. This can be illustrated by the action of naloxone (Narcan), an antagonist of opiates such as morphine. Naloxone counteracts opiate action in the central nervous system when given intravenously and is therefore used in the treatment of opiate overdose. The same drug, when swallowed, acts exclusively on the bowels; it is here used to treat constipation under opiate pain therapy and does not affect the pain-reducing effect of the opiate.

Oral

[edit]

The oral route is generally the most convenient and costs the least.[25] However, some drugs can cause gastrointestinal tract irritation.[26] For drugs that come in delayed release or time-release formulations, breaking the tablets or capsules can lead to more rapid delivery of the drug than intended.[25] The oral route is limited to formulations containing small molecules only while biopharmaceuticals (usually proteins) would be digested in the stomach and thereby become ineffective. Biopharmaceuticals have to be given by injection or infusion. However, recent research found various ways to improve oral bioavailability of these drugs. In particular permeation enhancers,[27] ionic liquids,[28] lipid-based nanocarriers,[29] enzyme inhibitors and microneedles[30] have shown potential.

Oral administration is often denoted as "PO" from "per os", the Latin word for "by mouth".

The bioavailability of oral administration is affected by the amount of drug that is absorbed across the intestinal epithelium and first-pass metabolism.[31]

Oral mucosal

[edit]

The oral mucosa is the mucous membrane lining the inside of the mouth.

Buccal

[edit]

Buccally administered medication is achieved by placing the drug between gums and the inner lining of the cheek.[32][33] In comparison with sublingual tissue, buccal tissue is less permeable resulting in slower absorption.[33]

Sublabial

[edit]

Sublabial administration is achieved by placing the drug between the lip and gum. The frenulum of the tongue may be irritated when in contact with corrosive materials but can be avoided with this route. It is usually used for medications such as nitroglycerin, for example.[34]

Sublingual

[edit]

Sublingual administration is fulfilled by placing the drug between the tongue and the lower surface of the mouth.[33] The sublingual mucosa is highly permeable and thereby provides access to the underlying expansive network composed of capillaries, leading to rapid drug absorption.[33]

Supralingual

[edit]

Supralingual administration is achieved by placing the drug above the tongue.[35][36][37] It is often the route of administration of choice when one would like the drug to bypass or alleviate the first pass effect on the drug after oral delivery.[37]

Intranasal

[edit]

Drug administration via the nasal cavity yields rapid drug absorption and therapeutic effects.[33] This is because drug absorption through the nasal passages does not go through the gut before entering capillaries situated at tissue cells and then systemic circulation and such absorption route allows transport of drugs into the central nervous system via the pathways of olfactory and trigeminal nerve.[33]

Intranasal absorption features low lipophilicity, enzymatic degradation within the nasal cavity, large molecular size, and rapid mucociliary clearance from the nasal passages, which explains the low risk of systemic exposure of the administered drug absorbed via intranasal.[33]

Involved subjects' positions.

Local

[edit]

By delivering drugs almost directly to the site of action, the risk of systemic side effects is reduced.[25]

Skin absorption (dermal absorption), for example, is to directly deliver drug to the skin and, hopefully, to the systemic circulation.[38] However, skin irritation may result, and for some forms such as creams or lotions, the dosage is difficult to control.[26] Upon contact with the skin, the drug penetrates into the dead stratum corneum and can afterwards reach the viable epidermis, the dermis, and the blood vessels.[38]

Parenteral

[edit]

The term parenteral is from para-1 'beside' + Greek enteron 'intestine' + -al. This name is due to the fact that it encompasses a route of administration that is not intestinal. However, in common English the term has mostly been used to describe the four most well-known routes of injection.

A peripheral IV placed on the hand.
A medical professional performs an intradermal (ID) injection.

The term injection encompasses intravenous (IV), intramuscular (IM), subcutaneous (SC) and intradermal (ID) administration.[39]

Parenteral administration generally acts more rapidly than topical or enteral administration, with onset of action often occurring in 15–30 seconds for IV, 10–20 minutes for IM and 15–30 minutes for SC.[40] They also have essentially 100% bioavailability and can be used for drugs that are poorly absorbed or ineffective when they are given orally.[25] Some medications, such as certain antipsychotics, can be administered as long-acting intramuscular injections.[41] Ongoing IV infusions can be used to deliver continuous medication or fluids.[42]

Disadvantages of injections include potential pain or discomfort for the patient and the requirement of trained staff using aseptic techniques for administration.[25] However, in some cases, patients are taught to self-inject, such as SC injection of insulin in patients with insulin-dependent diabetes mellitus. As the drug is delivered to the site of action extremely rapidly with IV injection, there is a risk of overdose if the dose has been calculated incorrectly, and there is an increased risk of side effects if the drug is administered too rapidly.[25]

Respiratory tract

[edit]

Mouth inhalation

[edit]
A dummy wears a nebulizer mask, used to administer inhaled medications.
  1. trachea (conducting zone)
  2. main bronchus (conducting zone)
  3. lobar bronchus (conducting zone)
  4. segmental bronchus (conducting zone)
  5. subsegmental bronchus (conducting zone)
  6. conducting bronchiole (conducting zone)
  7. terminal bronchiole (conducting zone)
  8. respiratory bronchiole (transitional respiratory zone)
  9. alveolar duct (transitional respiratory zone)
  10. alveolar sac (transitional respiratory zone)
  11. alveolus (transitional respiratory zone)
[43][44][45][46][47][48][49][50]

Inhaled medications can be absorbed quickly and act both locally and systemically.[26] Proper technique with inhaler devices is necessary to achieve the correct dose. Some medications can have an unpleasant taste or irritate the mouth.[26]

In general, only 20–50% of the pulmonary-delivered dose rendered in powdery particles will be deposited in the lung upon mouth inhalation.[51] The remainder of 50-70% undeposited aerosolized particles are cleared out of lung as soon as exhalation.[51]

An inhaled powdery particle that is >8 μm is structurally predisposed to depositing in the central and conducting airways (conducting zone) by inertial impaction.[51]

An inhaled powdery particle that is between 3 and 8 μm in diameter tend to largely deposit in the transitional zones of the lung by sedimentation.[51]

An inhaled powdery particle that is <3 μm in diameter is structurally predisposed to depositing primarily in the respiratory regions of the peripheral lung via diffusion.[51]

Particles that deposit in the upper and central airways are generally absorbed systemically to great extent because they are only partially removed by mucociliary clearance, which results in orally mediated absorption when the transported mucus is swallowed, and first pass metabolism or incomplete absorption through loss at the fecal route can sometimes reduce the bioavailability.[52] This should in no way suggest to clinicians or researchers that inhaled particles are not a greater threat than swallowed particles, it merely signifies that a combination of both methods may occur with some particles, no matter the size of or lipo/hydrophilicity of the different particle surfaces.[51]

Nasal inhalation

[edit]

Inhalation by nose of a substance is almost identical to oral inhalation, except that some of the drug is absorbed intranasally instead of in the oral cavity before entering the airways. Both methods can result in varying levels of the substance to be deposited in their respective initial cavities, and the level of mucus in either of these cavities will reflect the amount of substance swallowed. The rate of inhalation will usually determine the amount of the substance which enters the lungs. Faster inhalation results in more rapid absorption because more substance finds the lungs. Substances in a form that resists absorption in the lung will likely resist absorption in the nasal passage, and the oral cavity, and are often even more resistant to absorption after they fail absorption in the former cavities and are swallowed.

Research

[edit]

Neural drug delivery is the next step beyond the basic addition of growth factors to nerve guidance conduits. Drug delivery systems allow the rate of growth factor release to be regulated over time, which is critical for creating an environment more closely representative of in vivo development environments.[53]

See also

[edit]

References

[edit]
[edit]

Grokipedia

from Grokipedia
A route of administration is the method by which a or therapeutic agent is delivered into or onto the body to achieve its pharmacological effect, encompassing the pathway that influences absorption, distribution, , and . This approach is fundamental in , as it determines the 's —the fraction that reaches systemic circulation—and the onset, duration, and intensity of therapeutic action, with common examples including oral , intravenous injection, and topical application. Routes of administration have ancient origins, with oral ingestion and topical applications used by early civilizations such as the and for medicinal purposes. Parenteral routes, particularly intravenous administration, emerged in the 17th century through pioneering experiments by figures like , who used animal bladders and quills for infusions, and became clinically viable in the during cholera epidemics for fluid replacement. Routes of administration are typically classified into three major categories: enteral, parenteral, and topical (or local), each suited to specific clinical needs based on the drug's physicochemical properties and the patient's condition. Enteral routes involve passage through the , including oral, sublingual or buccal, and . Parenteral routes bypass the digestive system for faster or more reliable delivery, including intravenous, intramuscular, subcutaneous, and intradermal administration. Topical routes target localized areas or allow absorption, such as application to the skin, , nasal, ocular, or vaginal/. The selection of an appropriate route is influenced by multiple factors to optimize while minimizing risks, including the drug's stability, required speed of action, challenges, patient-specific considerations, and practical aspects such as convenience and cost. Each route carries distinct advantages and potential drawbacks. Overall, proper route selection enhances therapeutic outcomes and across medical practice.

Introduction

Definition and Scope

Routes of administration refer to the specific paths or methods by which therapeutic agents, such as drugs, are introduced into the body to produce desired systemic or localized pharmacological effects. This concept encompasses the deliberate selection of entry points that facilitate the drug's interaction with target tissues or organs, ensuring optimal therapeutic outcomes while minimizing adverse effects. The scope of routes of administration is broad, covering a range of techniques from non-invasive methods like to invasive procedures such as injection, with the choice profoundly influencing key pharmacokinetic parameters including , , and duration of effect. Broadly, these routes are categorized into enteral (involving the ), parenteral (bypassing the ), and topical or mucosal (applied to or mucous membranes for local or systemic absorption). Each category allows for tailored suited to the medication's properties and the patient's needs, spanning oral tablets, intravenous infusions, patches, and more. The importance of selecting an appropriate route lies in its direct impact on , safety, and patient outcomes, as it governs absorption rates—the speed at which the enters the bloodstream—and modulates first-pass , where hepatic enzymes metabolize a portion of the before it reaches systemic circulation, potentially reducing . For instance, routes avoiding the can achieve higher by circumventing first-pass effects, leading to faster onset and more predictable duration of action, which is critical for conditions requiring rapid intervention or sustained release. Ultimately, this foundational aspect of optimizes therapeutic precision, enhances compliance, and mitigates risks associated with suboptimal delivery.

Historical Development

The earliest known routes of drug administration date back to ancient civilizations, where oral ingestion and topical applications were predominant methods for delivering herbal remedies and other medicaments. In , around 1550 BCE, the documented over 700 medicinal formulas, primarily involving oral consumption of plant-based concoctions for treating ailments such as infections and digestive issues, alongside topical applications like ointments and poultices applied directly to the skin. Similarly, in , (c. 460–377 BCE), often regarded as the father of medicine, advocated for the use of herbal poultices—mixtures of plants such as and applied externally—to reduce and promote , emphasizing natural substances in numerous recorded remedies. These practices reflected a foundational understanding of through simple, non-invasive means, integrating observation of bodily responses with empirical trial. During the medieval period and into the , rectal administration via enemas emerged as a significant route, building on ancient precedents but gaining institutional prominence in . Enemas, or clysters, were routinely used from the onward to purge the body of supposed toxins, with physicians employing animal s or syringes to deliver herbal infusions, often for treating or fevers. A pivotal advancement in parenteral routes occurred in 1656 when English scientist conducted the first recorded intravenous injections in dogs, using a and animal bladder to administer substances like wine and opium, demonstrating the potential for direct bloodstream delivery despite rudimentary tools. In 1853, the invention of the by French surgeon Charles Pravaz—a piston syringe with a hollow silver needle—enabled subcutaneous and intramuscular injections, revolutionizing precise for conditions like . The marked rapid innovations in specialized routes, driven by pharmaceutical advancements and medical needs. In the 1920s, the discovery of insulin by and colleagues led to its first in humans on January 23, 1922, to 14-year-old Leonard Thompson, transforming treatment from fatal to manageable through regular injections. therapy advanced significantly in 1956 with the introduction of the first pressurized (MDI) by Riker Laboratories, delivering epinephrine or isoproterenol aerosols for relief and establishing pulmonary delivery as a targeted, patient-friendly option. The late saw the rise of systems, exemplified by the 1979 FDA approval of the patch for prevention, which used a membrane-controlled reservoir to provide sustained release through the skin, paving the way for broader applications like nicotine replacement. These milestones shifted drug administration toward more controlled, site-specific methods, influencing modern classifications of enteral, parenteral, and topical routes.

Classification

Enteral Routes

Enteral routes of administration involve the delivery of medications into the gastrointestinal () tract, where drugs are absorbed through the mucosa into the systemic circulation. This approach encompasses methods that utilize the digestive system for drug uptake, distinguishing it from routes that bypass the tract. The primary enteral methods include oral administration, where drugs are swallowed in forms such as tablets or capsules; rectal administration via suppositories or enemas; and nasogastric administration through a feeding tube inserted into the stomach. Oral delivery is the most common due to its simplicity, while rectal and nasogastric routes are employed when swallowing is impaired or for targeted delivery. Absorption via enteral routes primarily occurs in the , influenced by factors such as variations, enzymatic degradation, and motility. Drugs absorbed from the tract enter the and undergo first-pass in the liver, where enzymes metabolize a portion of the , reducing its to the systemic circulation. Oral can range from 0% to nearly 100%, depending on the compound's susceptibility to these processes. Enteral routes offer advantages such as being non-invasive and patient-friendly, facilitating self-administration in many cases. However, they are subject to disadvantages including variable absorption rates affected by intake, GI motility, and changes, which can delay onset and reduce predictability. For example, oral ibuprofen, a , is widely used for analgesia but may exhibit inconsistent absorption when taken with meals. In contrast, partially avoids the first-pass effect due to drainage via both portal and systemic veins, improving for certain drugs and making it suitable for or unconscious patients; rectal antiemetics like are employed in such scenarios to manage when oral intake is not feasible.

Parenteral Routes

Parenteral routes of administration involve the delivery of medications directly into the body through injections or s, bypassing the to achieve systemic effects. These methods utilize needles, syringes, or catheters to introduce drugs into tissues, vessels, or body cavities outside the digestive , ensuring more predictable absorption compared to oral routes. The primary parenteral methods include intravenous (IV), intramuscular (), subcutaneous (SC), and intradermal administration. Intravenous delivery can occur as a bolus injection for immediate effect or as a continuous for sustained release, directly accessing the stream. Intramuscular injections target muscle tissue, such as the deltoid or , while subcutaneous injections deposit drugs into the fatty layer beneath the skin, and intradermal injections place small volumes into the layer. Absorption characteristics vary by method and site. Intravenous administration provides 100% since the drug enters the circulation directly, without first-pass . In contrast, intramuscular and subcutaneous routes achieve dependent on local blood flow and tissue properties; for instance, the offers faster absorption due to higher compared to the gluteal muscle. These routes offer advantages such as rapid , ideal for emergencies or conditions requiring precise dosing, but they are invasive, carrying risks of , , and tissue damage at the injection site. Examples include intramuscular vaccines for stimulation and intravenous for targeted . Specific applications highlight their utility: intradermal injections are used for testing due to the 's immune-rich environment, eliciting localized reactions for , while subcutaneous insulin administration provides slower, sustained release for .

Topical and Mucosal Routes

Topical and mucosal routes involve the application of drugs directly to external surfaces such as the or non-gastrointestinal mucous membranes, including those of the eyes, ears, , oral cavity, lungs, and , to achieve primarily local effects or limited systemic absorption without involving the digestive tract. These methods are non-invasive and target specific sites for therapeutic action, such as treating conditions, ocular disorders, or providing rapid relief from via oral mucosa. Primary methods encompass transdermal patches for sustained skin delivery, ocular drops for eye conditions, otic solutions for ear infections, intranasal sprays for nasal congestion or vaccination, inhalation via aerosols or nebulizers for respiratory conditions like asthma, vaginal creams or suppositories for gynecological infections, and oral mucosal applications like sublingual tablets or buccal films. For instance, transdermal patches deliver drugs such as nicotine or fentanyl across the skin for systemic effects over hours or days, while ocular drops treat glaucoma by applying prostaglandins or beta-blockers directly to the cornea. Intranasal sprays, such as those for flu vaccines like FluMist, leverage the nasal mucosa for immune response induction, and sublingual nitroglycerin tablets provide quick vasodilation for chest pain. Buccal formulations, placed against the cheek, avoid swallowing and direct absorption into the bloodstream. Inhalation delivers bronchodilators like albuterol to the lungs for rapid local action in respiratory distress, and vaginal metronidazole treats bacterial vaginosis with minimal systemic exposure. Absorption via these routes varies significantly due to anatomical barriers; the skin's acts as a primary barrier, limiting systemic uptake to low levels for most hydrophilic or large-molecule drugs, often requiring enhancers for penetration. In contrast, mucosal routes enable faster absorption owing to their rich vascularity and thinner , as seen with sublingual , where the drug bypasses hepatic first-pass metabolism for onset within minutes via sublingual veins. Ocular absorption through the is inefficient, with only about 1-5% of applied drops reaching the anterior chamber for , leading to substantial nasolacrimal drainage and potential systemic exposure. These routes offer advantages like targeted localized action, which minimizes systemic side effects and gastrointestinal , and ease of self-administration for improved patient compliance, as with creams for eczema that provide effects with minimal percutaneous absorption (typically 1-7% systemically on intact ). However, disadvantages include poor penetration for polar or high-molecular-weight compounds across the skin, potential local or allergic reactions like , and limited drug loading capacity, restricting use to potent agents requiring low doses. Intranasal vaccines exemplify mucosal benefits by eliciting strong local immunity but face challenges from reducing residence time.

Factors Influencing Selection

Convenience and Patient Compliance

The convenience of a route of administration significantly influences compliance, with non-invasive options like oral delivery often preferred over invasive methods such as intravenous due to ease of use and reduced discomfort. In surveys, up to 79% favor oral tablets over injections or infusions when and are comparable, primarily for their simplicity in daily routines. Self-administration feasibility further enhances adherence, as routes enabling independent use—such as oral or subcutaneous—minimize reliance on healthcare providers and fit better into patients' lifestyles. Less frequent dosing schedules also play a key role, with showing higher compliance rates for once-daily regimens compared to multiple daily administrations. Patient-specific factors tailor route selection to improve compliance across diverse populations. In infants and young children, where may be difficult due to challenges or , the rectal route offers a practical alternative for delivering medications like laxatives for management. For adults with conditions requiring regular injections, such as , prefilled subcutaneous pens facilitate self-administration and boost adherence by simplifying the process and reducing injection-related anxiety compared to traditional vials and syringes. Patients with lifestyles prone to forgetfulness, including those with cognitive impairments like , benefit from patches, which provide steady delivery over days or weeks without daily prompting, leading to improved treatment persistence. Overall adherence rates underscore the impact of route complexity, with studies reporting around 50% non-adherence among on intricate regimens, such as multiple daily injections for chronic diseases. Oral routes exemplify high convenience for long-term conditions like , where simple pill-taking supports sustained compliance and better blood pressure control. In asthma management, advanced inhalation devices, including those with reminders, have demonstrated enhanced adherence by making dosing more intuitive and less error-prone than traditional methods. These practical aspects must be balanced against therapeutic requirements to optimize outcomes.

Therapeutic and Pharmacokinetic Considerations

The selection of a route of administration is fundamentally guided by therapeutic objectives, which determine whether the drug's action should be localized or systemic. Local administration targets specific sites to minimize systemic exposure and side effects, such as applying topical corticosteroids directly to rashes for effects confined to the affected area. In contrast, systemic routes like intravenous (IV) infusion are preferred for emergencies requiring immediate widespread distribution, such as epinephrine in , where rapid circulation ensures quick onset across the body. Pharmacokinetic properties, including and , further influence route choice to optimize efficacy and timing. (F) quantifies the fraction of an administered dose that reaches systemic circulation unchanged, calculated as: F=AUCtestAUCreference×100%F = \frac{\text{AUC}_{\text{test}}}{\text{AUC}_{\text{reference}}} \times 100\% where AUC represents the area under the plasma concentration-time curve, typically comparing oral to IV administration as the reference (F = 1 for IV). Oral routes often exhibit lower due to gastrointestinal absorption variability and hepatic first-pass , while IV achieves complete . varies significantly: IV delivery occurs in seconds by directly entering the bloodstream, whereas typically takes 30-60 minutes due to absorption and transit through the digestive system. Routes also affect drug distribution, particularly for barriers like the blood-brain barrier (BBB), which restricts (CNS) access for many therapeutics. Intranasal administration enables direct nose-to-brain transport via olfactory and trigeminal pathways, bypassing the BBB to enhance CNS delivery of drugs like peptides for neurological conditions. This route leverages the nasal cavity's proximity to the brain, allowing faster and more targeted distribution compared to systemic options that require higher doses to overcome BBB limitations. Specific examples illustrate these considerations in clinical practice. routes provide rapid local delivery to the lungs for (COPD), where bronchodilators like albuterol achieve onset within minutes by directly targeting airway , reducing systemic exposure. is advantageous in to bypass partial hepatic first-pass ; approximately 50% of rectally absorbed drugs enter systemic circulation via inferior and middle rectal veins, avoiding full liver processing and improving for analgesics or antiemetics in patients with impaired hepatic function.

Safety and Formulation Factors

Safety risks associated with routes of administration vary by method and can include , local , and systemic adverse effects. Parenteral routes, such as intravenous (IV) and intramuscular () injections, carry a heightened risk of due to breaching the skin barrier, with complications like abscesses or possible if aseptic techniques are not followed. IV administration specifically risks rapid drug delivery leading to overdose or severe cardiopulmonary effects, such as or arrhythmias, particularly with vasoactive agents. Topical and mucosal routes may cause local , including skin rashes from patches or corneal abrasions from , exacerbating discomfort in sensitive patients. Formulation requirements differ significantly across routes to ensure compatibility and efficacy. Parenteral formulations must be sterile and nonpyrogenic to prevent microbial contamination and endotoxemia, often achieved through aseptic processing and filtration as mandated by regulatory standards. Oral formulations require solubility enhancers, such as cyclodextrins or solid dispersions, for poorly water-soluble drugs to improve gastrointestinal absorption and bioavailability without compromising stability. Transdermal systems necessitate pressure-sensitive adhesives, like acrylic or silicone-based polymers, to maintain skin contact while controlling drug release and minimizing residue upon removal. Contraindications for specific routes help mitigate these risks. The oral route is contraindicated in patients with severe or , as it impairs absorption and increases aspiration risk, necessitating alternatives like IV or . IM injections are contraindicated in individuals with bleeding disorders or on anticoagulants, due to the potential for formation from vascular damage. Representative examples illustrate these factors in practice. Liposomal formulations for IV chemotherapy agents, such as , encapsulate the drug to reduce by altering distribution and clearance, allowing higher doses with lower systemic exposure. Buffered , pH-adjusted to approximately 7.4 to match tear fluid, prevent stinging and irritation upon instillation, enhancing patient tolerance for repeated use.

Emerging Developments

Novel Delivery Methods

Microneedle patches represent a painless transdermal alternative to hypodermic injections, utilizing arrays of microscopic needles to deliver drugs or vaccines directly into the skin's outer layers without reaching deeper nerves or blood vessels. These patches enhance patient compliance by eliminating needle phobia and sharps waste, while enabling controlled release through dissolving, coated, or hollow designs. The BD Soluvia™ system, approved by the FDA in 2012, was the first microneedle device cleared for intradermal vaccine delivery, such as influenza vaccines, demonstrating improved immune responses in clinical studies. In the 2020s, advancements have focused on vaccine applications, including experimental dissolving microneedle patches for COVID-19 and influenza, which showed comparable immunogenicity to intramuscular injections in preclinical models with reduced dosing volumes. Implantable devices offer long-acting subcutaneous delivery, providing steady drug release over months to years, which minimizes frequent dosing and improves adherence for chronic conditions. Probuphine, a subdermal implant consisting of four ethylene-vinyl acetate (EVA) rods, received FDA approval in 2016 for maintenance treatment of in stable patients, delivering therapeutic levels for up to six months via insertion in the upper arm. Clinical trials demonstrated that Probuphine achieved steady-state plasma concentrations of approximately 1 ng/mL (range: 0.3–2.4 ng/mL), comparable to daily sublingual dosing, with reduced risks of misuse due to its tamper-resistant design. These implants expand parenteral routes by enabling site-specific, zero-order kinetics release, as seen in similar systems for contraceptives and antipsychotics. Targeted nanoparticles facilitate site-specific parenteral delivery by engineering particles with ligands or surface modifications to homing in on diseased tissues, while also enhancing mucosal uptake through mucoadhesive or mucopenetrating properties that overcome barriers like mucus clearance. Polymeric nanoparticles, such as those coated with (PEG), improve by prolonging circulation and enabling at mucosal sites, with studies showing up to 10-fold increased uptake in intestinal or nasal models compared to free drugs. For instance, chitosan-based nanoparticles have been developed for nasal mucosal delivery of insulin, achieving 20-30% relative in animal models by promoting paracellular transport and mucoadhesion. These systems reduce off-target effects and dosing frequency, with ongoing clinical translations for vaccines and applications. Buccal films provide rapid absorption via the , bypassing first-pass for faster onset, particularly suited for analgesics and antiemetics. FDA-approved examples include Onsolis (fentanyl buccal soluble film), cleared in 2009 for breakthrough , which dissolves in 15-30 minutes to deliver 200-1600 mcg doses with peak plasma levels in 30-60 minutes, offering analgesia within 15 minutes in clinical use. Similarly, Belbuca (buprenorphine buccal film), approved in 2015, treats opioid dependence with strengths from 75-900 mcg, achieving 30-50% higher than sublingual tablets due to enhanced mucosal retention. These films use polymers like for unidirectional release toward the mucosa, improving patient convenience over liquids or tablets. Iontophoresis enhances topical penetration by applying a mild (typically 0.5-2 mA) to drive charged drug ions across the , increasing flux rates by 10-100 times for molecules like peptides without skin disruption. FDA-cleared devices, such as the Iontophor Patch system, deliver lidocaine for , achieving dermal concentrations sufficient for pain relief in 10-20 minutes during clinical procedures. Although some products like the Zecuity iontophoretic patch were recalled in 2016 due to safety concerns, approved systems for and drugs continue to support enhanced delivery in and . This method expands topical routes for hydrophilic compounds otherwise limited by passive . Ongoing research in gene therapy highlights the intravenous (IV) and intrathecal routes for delivering viral vectors, particularly adeno-associated virus (AAV) vectors, to target central nervous system disorders. For instance, onasemnogene abeparvovec (Zolgensma), approved in 2019 for spinal muscular atrophy (SMA) via IV administration in infants under two years, is now under investigation for intrathecal delivery in older pediatric patients to achieve broader transduction with lower doses and reduced immunogenicity risks. The phase III STEER trial met its primary endpoint in December 2024, demonstrating statistically significant improvements in motor function for treatment-naïve patients aged 2-18 years. Intrathecal administration enhances central nervous system penetration compared to systemic IV routes, as demonstrated in preclinical models where it minimizes off-target liver transduction. Advancements in 3D-printed oral dosage forms are enabling personalized drug release profiles tailored to individual patient needs, such as varying release kinetics for chronic conditions. These forms allow for precise control over dosage, shape, and multilayer structures to achieve sustained or pulsatile release, improving adherence in pediatric and geriatric populations.01766-3) Recent studies have shown that 3D printing facilitates multidrug combinations in single polypills, optimizing therapeutic outcomes while reducing polypharmacy burdens. A key challenge in route optimization is enhancing for orally administered peptides, which face enzymatic degradation and poor permeability in the . Nanotechnology addresses this through carriers like chitosan-based nanoparticles, which protect peptides and promote absorption via mucoadhesion and paracellular transport, with preclinical data indicating up to 10-fold bioavailability improvements. As of 2025, clinical trials are evaluating lipid nanoparticles and polymer-peptide conjugates for oral analogs, reporting enhanced systemic exposure in phase II studies without significant adverse effects. Future trends point toward wireless-controlled implants for on-demand drug release, integrating microelectromechanical systems to enable remote activation via external signals like ultrasound or magnetic fields. These devices offer precise dosing adjustments, potentially reducing the need for frequent administrations in chronic diseases such as diabetes or cancer. Prototypes have demonstrated controlled release of multiple drugs from biodegradable reservoirs, with biocompatibility confirmed in animal models. Artificial intelligence (AI) is emerging as a tool for optimizing route selection by analyzing patient-specific data, including , , and real-time biomarkers, to predict the most effective administration method. models can recommend routes like over oral for poor absorbers, improving efficacy while minimizing toxicity, as shown in simulations integrating electronic health records. Research on ocular and intravitreal routes is expanding to develop long-acting implants that sustain levels in the posterior segment, addressing challenges like frequent injections for conditions such as age-related . Biodegradable inserts and nanoparticle-laden hydrogels are in phase III trials, providing release over 6-12 months and reducing injection frequency by up to 80%. These innovations prioritize minimally invasive periocular alternatives to traditional intravitreal injections. In , underexplored applications of advanced routes include nanogel-based mucosal delivery for and therapeutics, enhancing immune responses in and companion animals via intranasal or . Long-acting injectables, such as subcutaneous implants, are gaining traction for sustained release, with studies showing improved compliance and reduced resistance risks in and . Precision trends, including targeted nanoparticles, are addressing species-specific barriers to .

References

User Avatar
No comments yet.